| Half-life | 7 hours |
| Tmax | 1 h |
| Bioavailability | 36 % (approx) |
| Protein Binding | 60 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | No amphetamine-like metabolites; preferred over selegiline for tolerability. |
Severity: Moderate
Adverse Effects:
Headache, arthralgia, depression, nausea
Contraindications:
Use with other MAO inhibitors; serotonergic agents may cause serotonin syndrome
Precautions:
Avoid severe tyramine overload; monitor for serotonin syndrome if combined with antidepressants